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Simple Summary: Chronic hepatitis C virus (HCV) infection is a common cause of liver cancer
in the developed world. Although anti-viral treatment can cure HCV infection, the risk of cancer
development remains in individuals with consequent advanced fibrosis or cirrhosis. In this study,
we show that HCV can influence transposable DNA elements called L1 retrotransposons. These are
mobile genetic elements that can negatively alter the host genome, potentially promoting cancer
development. L1 elements are known to be activated in several cancer types, including liver cancer.
Hence, we suggest a novel pathway involved in liver cancer development in patients with chronic
HCV, including those with active infection as well as after viral clearance.
Abstract: Hepatitis C virus (HCV) is a common cause of hepatocellular carcinoma (HCC). The activation
and mutagenic consequences of L1 retrotransposons in virus-associated-HCC have been documented.
However, the direct influence of HCV upon L1 elements is unclear, and is the focus of the present study. L1
transcript expression was evaluated in a publicly available liver tissue RNA-seq dataset from patients with
chronic HCV hepatitis (CHC), as well as healthy controls. L1 transcript expression was significantly higher
in CHC than in controls. L1orf1p (a L1 encoded protein) expression was observed in six out of 11 CHC
livers by immunohistochemistry. To evaluate the influence of HCV on retrotransposition efficiency, in vitro
engineered-L1 retrotransposition assays were employed in Huh7 cells in the presence and absence of an
HCV replicon. An increased retrotransposition rate was observed in the presence of replicating HCV RNA,
and persisted in cells after viral clearance due to sofosbuvir (PSI7977) treatment. Increased retrotransposition
could be due to dysregulation of the DNA-damage repair response, including homologous recombination,
due to HCV infection. Altogether these data suggest that L1 expression can be activated before oncogenic
transformation in CHC patients, with HCV-upregulated retrotransposition potentially contributing to HCC
genomic instability and a risk of transformation that persists post-viral clearance.
Keywords: L1; HCV; retrotransposition; DNA damage; hepatocellular carcinoma
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1. Introduction
Hepatocellular carcinoma (HCC) is the sixth most common type of cancer and fourth
most frequent cause of cancer-related deaths worldwide [1]. One of the most important
aetiological factors associated with HCC development is chronic hepatitis B or C virus
(HBV or HCV) infection [2]. A major advance in the field has been the introduction of
direct-acting antivirals (DAAs) targeting HCV infection, which induce very high rates of
sustained viral clearance, and now the majority of the patients treated with DAAs are
cured of HCV infection [3]. However, while successful treatment of HCV reduces the risk
of developing HCC, this risk is not completely eliminated, especially amongst patients
who have advanced fibrosis or cirrhosis [4]. A large proportion of patients presenting with
HCC have incurable disease at presentation, due to late detection when curative treatments
(transplantation, resection, ablation) cannot be offered. This negatively impacts survival.
Early detection of HCC greatly increases the likelihood of curative therapies being offered.
This presents an unmet need—a better understanding of the HCC risk in HCV patients is
needed in order to develop tools for improved HCC early detection and outcomes [5,6]. We
believe that understanding the molecular mechanisms that lead to hepatocarcinogenesis in
HCV will help to achieve this.
The molecular mechanism for the development of HCV-associated HCC remains
unknown and is likely to be multifactorial, involving multiple molecular pathways. Upon
HCV infection, the virus modulates the host cells for its own survival and replication.
The HCV genome is directly translated at the rough endoplasmic reticulum (ER) as a
single polyprotein precursor that is eventually cleaved by cellular and viral proteases
into ten mature products. These virus-encoded proteins then further participate in the
process of viral replication and assembly [7]. Overall, the HCV replication process induces
oxidative and ER stress in the liver cells, promoting hepatocarcinogenesis [8–10]. Moreover,
HCV infection has been demonstrated to induce autophagy [11], the innate immune
response [12] and to impair DNA damage repair (DDR) pathways [13–15]. Hence, HCV-
encoded proteins interact with various host proteins and dysregulate various pathways,
contributing towards hepatocarcinogenesis. Several of these changes are epigenetic in
nature [16,17], a number of which have been shown to persist even after HCV infection
clearance by DAA treatment [18,19].
Okamoto et al. previously demonstrated global DNA hypomethylation (indicated
by the L1 promoter) as a consequence of HBV and HCV infection in a humanised mouse
model of hepatitis virus infection [20]. Furthermore, Shukla et al. demonstrated L1
(an autonomous mobile genetic element, or retrotransposon) activation and its promotion
of oncogenic signalling pathways in HBV- and HCV-related HCC [21]. Incidentally, active
L1 retrotransposition in virus (HCV or HBV)-associated HCC was also reported by the
Pan-Cancer Whole-Genome Analysis (PCWGA) consortium study, which included HCC
cases [22]. Active L1 retrotransposition has also been observed in cases of alcohol-related-
liver-disease-associated HCC [22,23]. However, the rate of somatic L1 retrotransposition
was lower in alcohol-related cases (~14%; five out of 37 individuals) compared to virus-
associated HCC (~32%; 97 out of 306 individuals) [21–23]. Somatic retrotransposition in
HCC has been hypothesised to be an early event in hepatocarcinogenesis, at least in the
presence of HBV-HCC, where it has been detected in the non-tumour liver tissue of one
HBV-HCC case [21]. Recently, HCV infection has also been associated with the loss of DNA
methylation in specific repeat elements (L1s and Alu), showing a stepwise hypomethyla-
tion from normal liver to HCV-cirrhosis to HCV-HCC [24]. It is well established that L1
elements activated in various cancer types are involved in somatic structural variations,
leading to cancer evolution, with additional roles in human cancer development also
being implicated [22,25].
Hence, we hypothesise that L1s are activated in CHC patients, due to virus-assisted
epigenetic remodeling and suppression of host defense factors. We aimed to confirm this
in human samples and to evaluate the influence of HCV on the process of active retro-
transposition using in vitro models. Once activated, L1s may promote genomic instability,
Cancers 2021, 13, 5079 3 of 17
contributing towards cancer development even after HCV clearance. These mechanistic
understandings may help with future therapeutic or cancer-preventative approaches for
CHC patients.
2. Materials and Methods
2.1. Cell Lines and Chemical Inhibitors
The parental line Huh7 (a kind gift from Jean Dubuisson, Institut Pasteur de Lille,
Lille Cedex, France) and its derivative line Huh7-J17 were routinely maintained in RPMI
1640 media (Sigma, St. Louis, MO, USA, R5886) with 10% fetal bovine serum, 1% penicillin
and streptomycin and 1% L-glutamine. Huh7-J17 cells stably express an HCV sub-genomic
replicon encoding a firefly luciferase reporter and a puromycin resistance marker (separated
by the foot-and-mouth-disease virus (FMDV) 2a self-cleavage site) in the genotype 2a HCV
strain JFH1 ∆E1E2 background, as described previously [26,27]. Hence, 2 µg/mL puromycin
(Sigma P8833) was added into the media of Huh7-J17 cells to maintain the selection of
HCV replicon-expressing cells. Cells were routinely passaged and maintained in T75 flasks
and were grown at 37 ◦C, 5% CO2, in a humidified incubator and tested for Mycoplasma
once in every 2 months. Details of chemical inhibitors used in the study are as follows:
PSI7977 (Sofosbuvir, HCV NS5B polymerase inhibitor, Adooq Biosciences, Irvine, CA, USA,
A11529), KU-55933 (ATMi, TOCRIS, Bristol, UK, 3544), VE-821 (ATRi, Axon, Axon Medchem,
Groningen, The Netherlands, 1893), SRA-737 (CHK1i, Selleckchem, Huston, TX, USA, S8253).
Treatment conditions are mentioned in the text and figure legends.
2.2. Patient Samples
Archived diagnostic formalin-fixed paraffin-embedded (FFPE) liver biopsies from
patients with HCV with or without associated HCC and non-HCV without HCC were
obtained from the Newcastle Cancer Centre Biobank. All patients had provided written
consent for the use of their tissues for research purposes. Ethical approval was obtained
for the use of FFPE CHC patient biopsies (study reference: NAHPB-126) and non-HCV
patient biopsies (biobank reference: 116370) by the National Research Ethics Service (NRES)
Committee North East (REC ref: 12/NE/0395), sponsored by NUTH Trust R&D (Ref: 6579).
2.3. Plasmid Transfection
The indicated cells were seeded onto 6-well-plates and transfected the next day at approx-
imately 80–90% confluence with appropriate plasmids using TransIT-LT1 transfection reagent
(Mirus Bio., Madison, WI, USA, MIR 2304) in a 1:3 ratio as per the manufacturer’s instructions.
2.4. Retrotransposition Assay
Two different reporter systems were used to assess the active retrotransposition rates
in the cell lines. The plasmids used for the assays were a kind gift from Dr Jose Luis
Garcia-Perez, Institute of Genetics and Cancer, University of Edinburgh.
(a) EGFP as a reporter system: Cells were seeded onto a 6-well plate format and the
following day were transfected with 1 µg of retrotransposition reporter plasmid containing
an EGFP cassette interrupted by an intron so that EGFP expression occurred only after a
successful cycle of retrotransposition, leading to EGFP splicing and integration into the
genome. Either 99-GFP-LRE3 or 99-UB-GFP-LRE3 (retrotransposition competent) plasmid
containing an EGFP-based retrotransposition cassette and puromycin resistance gene or
corresponding negative control JM111 plasmid (retrotransposition incompetent due to a
260ARR-AAA262 mutation nearer to the C-terminus of ORF1) were used [28,29]. Five
days after transfection, FACS analysis of live cells was carried out to check EGFP-positivity
using an NxT Attune flow cytometer and with data analysis accomplished using FCS
Express 7 software. SSC-FSC scatter plots were used to select single-cell populations and
EGFP-positive populations were gated based on untransfected and JM111-transfected
cells. In parallel, the cells were pelleted for genomic DNA extraction using a DNeasy
Blood and Tissue kit (Qiagen GmbH, Hilden, Germany, 69504) that was further analysed
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quantitatively by Taqman qPCR using 2× Taqman genotyping qPCR master mix (Thermo
Fisher Scientific Inc., Waltham, Massachusetts, USA, 4371353) and QuantStudio™ 7 flex
Real-Time PCR system to determine the EGFP insertion rate. EGFP copy numbers were
normalised to RNaseP and calculated using the ∆∆Ct quantification method. The primers
and probe set utilised were: GFP_F: GAAGAACGGCATCAAGGTGAAC; GFP_R: GGT-
GCTCAGGTAGTGGTTGTC; GFP Probe: (6FAM)-AGCGTGCAGCTCGCCGACCA(BHQ1)
and RNaseP copy number assay with VIC-MGB probe (Applied Biosystems Inc., Waltham,
MA, USA 4401631).
Where mentioned, retrotransposition was carried out in the presence of the indicated
DDR pathway inhibitor in Huh7 cells. The inhibitors were added 3 days after transfection,
along with 2 µg/mL puromycin to enrich for transfected cells. The treatment continued for
a further 3–4 days. A no-inhibitor control with only puromycin treatment was always run
in parallel.
(b) Blasticidin resistance as a reporter system: Huh7 and Huh7-J17 were seeded onto
a 6-well-plate format and next day transfected with 1 µg wild-type L1 retrotransposition
plasmid (pJJ101/L1.3), containing a blasticidin-based retrotransposition cassette or a mutant
L1 retrotransposition plasmid (pJM105/L1.3mut, with a missense mutation (D702Y) in the
reverse transcriptase domain of the ORF2 protein [30], or pcDNA6.1-blast plasmid as a
positive control for the selection. Five days after transfection, the cells were harvested and
transferred to 10-cm dishes with 4 µg/mL of Blasticidin (Sigma, SBR00022). Fresh blasticidin
media was added every 3 days and the selection continued for a further 14–21 days to select
blasticidin resistant colonies. To quantify L1 retrotransposition, the colonies were fixed with
methanol and stained with 0.4% crystal violet (Sigma, C0775). Colonies were counted using
an automated colony counter (Oxford Optronix, Milton, Abington, UK).
2.5. DNA Damage Repair Plasmid Re-Joining Assays
The homologous recombination repair (HRR) and non-homologous end joining repair
(NHEJ) activity of the indicated cell lines was assessed by means of plasmid re-joining
assays using pDRGFP or pimEJ5GFP reporter plasmids with pCBASce1, respectively,
following established protocols in our lab [31]. In brief, pDRGFP contains an in vivo
homologous recombination substrate that is composed of two differentially mutated GFP
genes oriented as direct repeats and separated by a drug selection marker that can be
excised by I-SceI. pCBASce1 expresses the I-SceI endonuclease that introduces a DSB at an
I-SceI site. Upon successful repair, GFP is expressed in the cells and thus is an indicator of
HRR. The pimEJ5GFP plasmid is an I-SceI-based chromosomal break reporter for NHEJ. In
this reporter, end joining between two distal tandem I-SceI recognition sites restores an
EGFP expression cassette, caused by deletion of the intervening pgkPURO cassette; thus,
GFP expression is an indicator of NHEJ.
2.6. X-ray Irradiation Sensitivity Assay
Indicated cells were seeded onto 10-cm dishes and exposed to 2 Gy or 4 Gy X-ray
the following day using Gulmay X-ray Generator (Model No. RS320, Serial No. GM0092,
max 320 kV, Surrey, UK). Untreated cells were used as controls. The media was changed
24 h after X-ray exposure and then dishes were left undisturbed for 2–3 weeks to develop
colonies. The colonies were fixed with methanol and stained with 0.4% crystal violet and
measured using an automated colony counter. Plating efficiency % was calculated as
(no. of colonies formed/no. of cells plated) × 100 (1)
and survival fraction % was calculated as
(plating efficiency in treatment group/plating efficiency in untreated
conditions) × 100. (2)
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2.7. Immunohistochemistry (IHC)
L1orf1p IHC was performed on a Ventana Discovery XT system, using standard
protocol. In short, antigen retrieval was performed using Discovery CC1 buffer (Roche
Diagnostics GmbH, Mannheim, Germany 06414575001 (950-500)), followed by incuba-
tion with the primary antibody against L1orf1p (1:2000, Mouse Monoclonal, MABC1152,
Merck, Darmstadt, Germany), followed by anti-mouse-HRP secondary antibody (Roche
05266556001 (760-150)). An expert liver pathologist assessed the staining.
2.8. Western Blot Analysis
Western immunoblotting of whole-cell lysates was performed as described previously [32].
The primary antibodies used were anti-NS5A (mouse monoclonal, a kind gift from Charles M.
Rice, Rockfeller University, New York , NY, USA), anti-L1orf1p (mouse monoclonal, Merck,
MABC1152) and anti-GAPDH (rabbit monoclonal, Sigma, SAB2108266).
2.9. Luciferase Assay
The cells were lysed with passive lysis buffer (Promega, Madison, WI, USA) and
luciferase activity was measured using luciferase assay reagent (Promega, E1500) and an
Omega plate reader as per the instructions.
2.10. Bioinformatics
Human HCC RNAseq data were downloaded from The Cancer Genome Atlas Hepa-
tocellular Carcinoma (TCGA-LIHC) project and RNAseq data of CHC patients and healthy
controls GSE84346 were obtained from the NCBI GEO database. The reads were mapped to
the human L1-Ta sequence (5′UTR-promoter, Genbank: L19092) by BLAT alignment using
an in-house algorithm to obtain L1 counts (Python script can be provided upon request).
The counts were normalised by the total number of reads in each library and expressed
here as counts per million.
2.11. Statistical Analysis
GraphPad Prism software (GraphPad 8.0 and 9.0, San Diego, CA, USA) was used
for statistical analysis. p-values < 0.05 were considered significant. Mean ± standard
errors are shown in figures where applicable. * = p < 0.05, ** = p < 0.01, *** = p < 0.001,
**** = p < 0.0001. Data were analysed using the one-sample t-test (for fold change), Student’s
t-test (2 groups) or one- or two-way ANOVA with Tukey’s multiple comparison correction
when required (3 groups).
3. Results
3.1. L1 Expression Is Upregulated in Non-Tumour Tissue of Patients with Chronic Hepatitis
To evaluate L1 activation in the liver of chronic hepatitis C patients prior to the
development of HCC, we analysed a publicly available RNAseq dataset for a cohort
of CHC patients (n = 14) and control (healthy, n = 6) individuals (GSE84346). There
was significant upregulation of L1 transcripts in the livers of CHC patients (Figure 1A).
Likewise, interrogation of the RNAseq dataset of the TCGA-LIHC study revealed the
upregulation of L1 expression in the non-tumour livers of patients with a history of viral
hepatitis compared to patients with no history of any known HCC risk factors (Figure 1B).
However, upon cancer development, L1 was found to be upregulated in all the HCC
cases irrespective of the underlying aetiology (Figure 1B). We also evaluated the presence
of L1orf1-encoded protein (L1orf1p) expression by IHC in HCV-infected liver biopsies
from our own biobank (Ref. no. NAHPB-126). Again, L1orf1p expression was observed
in the non-tumour tissue of some individuals (six out of 11, ~54%), years before HCC
development. In two of the cases with subsequent diagnostic HCC biopsy tissue available,
the earlier non-tumour L1 status matched that of the HCC (i.e., positive remained positive
and negative remained negative) (Figure 1C). We also analysed the pre-HCC liver biopsies
in the case of non-viral fatty liver disease patients with alcohol related liver disease and
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metabolic syndrome from our own biobank (reference: 116370). One out of five (20%)
non-tumour livers exhibited L1orf1p positivity. Similarly, there is a trend of an increase in
L1 transcripts in the non-tumour tissue of patients with alcohol-related HCC, but it did not
reach statistical significance when compared to individuals with no history of any known
HCC risk factors (TCGA-LIHC RNAseq data, Figure S1). Hence, the data demonstrate
that L1s can be activated in a chronically diseased pre-neoplastic liver, especially when
associated with HCV infection, and may contribute to cancer development.
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(C). * p < 0.05, **** p < 0.0001, unpaired t-test (A) and two-way ANOVA (B). Key: CHC = Chronic
Hepatitis C patients; NT = Non Tumour; TCGA = The Cancer Genome Atlas; LIHC = Liver Hep-
atocellular Carcinoma; HCC = Hepatocellular Carcinoma; HCV = Hepatitis C Virus; L1 = Long
interspersed repeat element 1; L1orf1p = L1 open reading frame 1 encoded protein.
3.2. HCV Activates L1 Retrotransposition
To evaluate the direct influence of HCV infection on L1 retrotransposition, Huh7-J17 cells
stably expressing an HCV sub-genomic replicon (HCV genome without envelope proteins
fused with the puromycin-resistance cassette and luciferase expression cassette) were em-
ployed [26,27]. Huh7-J17 cells were also positive for luciferase activity, which decreased upon
treatment with PSI7977 (sofosbuvir, a NS5B polymerase inhibitor that inhibits virus replica-
tion) in a dose-dependent manner (Figure 2A), confirming the presence of the HCV replicon.
The presence of the viral replicon was also further confirmed by Western blotting, showing
the expression of the HCV NS5A protein (Figure 2B top panel and Figure S2). Similarly to
CHC patient livers, upregulation of L1orf1p was observed in Huh7-J17 compared to Huh7
cells (Figure 2B bottom panel and Figure S2).
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incompetent and it is thus used as a negative control (C). The results of the retrotransposition assay in Huh7 cells in the
presence and absence of HCV: graph representing fold change (FC) in the number of retrotransposition (RTN)-positive
cells observed via FACS analysis 5 days after transfection with UB-GFPLRE3 plasmid, where the negative gate was set
using cells transfected with UB-GFPJM111 plasmid, n = 4 independent repeats (D), quantification of GFP insertions in
the genome using RNaseP as a control, n = 3 technical replicates of one representative Taqman qPCR assay (E) and
blasticidin-r sistant colonies representative of active retrotransposition events, visualised via crystal vi let staining 3 weeks
after selecting cells with blasticidin. Blasticidin selection was started 5 d ys after transfection with a retrotransposition
plasmid-containing blasiticidin indicator cassette (L1.3wt r negative control plasmid L1.3mut, which co tains a missense
mutation (D702Y) in the reverse transcriptase domain of L1ORF2-protein, rendering it retrotransposition incompetent, and
pcDNA6.1, constitutively expressing a blasticidin resistance cassette as a positive control for transfection efficiency and
blasticidin resistance). The image is representative of 3 independent repeats done in duplicates. Numbers represent the
number of colonies in the plate (F) and the graph represents the fold change in number of colonies representing active
retrotransposition taking Huh7 cells as control (G). * p < 0.05, ** p < 0.01, **** p < 0.0001, one-sample t-test (D,G) and
one-way ANOVA with Tukey’s multiple testing correction (E). Detailed information about the Western blotting can be
found in Figure S2. Key: GFP = Green Fluoresc nt Protei ; RTN = Retrotransposition; FC = Fold Change; TSD = T rget Site
Duplication; FACS = Fluore cence Activated Cell Sorting; FL-L1 = Full Length L1 element; NS5A = nonstructural protein 5A;
L1orf1p = L1 open reading frame encoded protein; GAPDH = Glyceraldehyde 3-phosphate dehydrogenase; UB = Ubiquitin;
HCV = Hepatitis C Virus; SE = Standard Error.
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Next, we compared the retrotransposition efficiency of the Huh7-J17 cell line with the
corresponding parental or naïve Huh7 cells via an in vitro EGFP-based retrotransposition
assay assessed using FACS and PCR analysis (Figure 2C). A significant increase in cells
undergoing active retrotransposition was observed in Huh7-J17 cells compared to the
Huh7 control cells, as indicated by an increased number of EGFP-positive cells by FACS
analysis (fold change ~3.2, Figure 2D and Figure S3). The insertion of the L1-EGFP plasmid
in the genome was further verified via genomic PCR to detect the intron-less genomic
GFP sequence and was quantified via Taqman qPCR, revealing a ~2.9-fold increase in
retrotransposition efficiency in Huh7-J17 cells with the HCV replicon compared to the
naïve cells (Figure 2E and Figure S4). The influence of HCV replication on active retrotrans-
position was further independently verified using a blasticidin-based retrotransposition
assay, wherein the attainment of blasticidin resistance acts as a marker of active retrotrans-
position [29]. Again, a significant increase in blasticidin-resistant colonies were observed in
Huh7-J17 compared to Huh7, indicating an increased retrotransposition rate in the cells in
the presence of HCV RNA (fold change: 6.8 ± 1.36, n = 3, Figure 2F,G). As expected, cells
transfected with the L1.3-mutant plasmid exhibited no colonies, proving that the colonies
obtained in L1.3wt set were retrotransposition-specific. Moreover, cells transfected with the
pcDNA6.1-blast control plasmid developed a complete lawn in both the cell lines due to the
survival of all the transfected cells (Figure 2F). However, when seeded at a limited density,
the ability to attach and survive under blasticidin selection of Huh7-J17 cells transfected
with the control pcDNA6.1 blast plasmid was about 4.5-fold lower than Huh7 cells under
similar conditions (Figure S5). In spite of lower colonies in Huh7-J17 cells transfected with
pcDNA6.1, there were higher colonies in Huh7-J17 cells transfected with L1.3wt compared
to Huh7 cells in respective conditions, thus supporting the conclusion that the active L1
retrotransposition rate is higher in Huh7-J17 cells compared to Huh7 cells.
3.3. HCV Potentially Upregulates L1 Retrotransposition via the Inhibition of DNA Damage
Repair Pathways
For a successful round of L1 retrotransposition, an L1 element has to transcribe and
translate an mRNA to obtain its two encoded proteins (L1orf1p and L1orf2p), which then
bind with the transcript, forming a L1 ribonucleoprotein complex (RNP) [33]. The L1-RNP
complex in the nucleus reverse transcribes the transcript and inserts a new genomic lo-
cation mainly via a molecular mechanism known as target-primed reverse transcription
(TPRT) [34,35]. In short, the L1orf2p-encoded endonuclease domain makes a DNA nick
on one strand of the host genome at the AT-rich consensus sequence (5′-TTTT/AA-3′
consensus) and the resulting 3′-OH end is extended by the reverse transcriptase domain of
L1orf2p that makes a DNA copy from the L1 RNA, used as a template. Less frequently,
L1 integration can also occur independently of L1-endonuclease activity, using pre-existing
chromosomal DNA breaks [36]. Hence, the process of retrotransposition is controlled at
various steps by several nuclear and cytoplasmic proteins [37]. There are several reports
demonstrating the effect of DNA repair factors on L1 retrotransposition but observations
are inconsistent between studies; for example, an activating role as well as an inhibitory role
of ATM on L1 retrotransposition has been reported [38,39]. Recently, a systematic search for
host factors affecting L1 mobility was carried out via whole genome siRNA screening and
identified double-strand DNA break (DSB) repair, especially BRCA1-dependent homolo-
gous recombination repair (HRR), and Fanconi anemia (FA) factors as potent inhibitors of
L1 activity in HeLa cells [40].
Since HCV is known to impair DNA repair mechanisms, we used a colonogenic
assay to first compare the sensitivity of Huh7 and Huh7-J17 cells in response to a potent
DNA damaging agent, i.e., ionising radiation (IR), which causes a complex spectrum of
both DNA single-strand breaks (SSBs), as well as DSBs. Huh7-J17 cells were found to
be significantly more sensitive to IR compared to parental Huh7 cells (Figure 3A,B). It is
noteworthy that the non-irradiated colonogenic efficiency of Huh7-J17 cells was about
half that of the parental Huh7 cells (~26% Huh7-J17 versus ~56% for Huh7), indicating an
intrinsic stress in these cells due to the presence of HCV (Figure 3C).
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Compared to SSBs, DSBs are more lethal to cells if unrepaired. There may be roles for
either HRR or non-homologous end joining (NHEJ) pathways in the repair of IR-induced
DSBs in these cells. Thus, we next used plasmid-base reporter assays to test HRR and
NHEJ pathways in Huh7 d Huh7-J17 cells. The reporter assays revealed signific nt
downregulation of the HRR pathway in Huh7-J17 cells compared to Huh7 parental cells
(Figure 5E). Of note, there was no significant influence f the HCV replicon observ d on
the NHEJ pathway (Figure 5F). Hence, we postulated that the HRR pathway may influence
the regulation of L1 retrotranspositio in Huh7 cells.
We therefore examined the effect of blocking the DNA damage response enz m s
on L1 retrotransposition frequencies in the Huh7 cell line using small molecule inhibitors
that target ATM (KU-55933, 10 µM), ATR (VE-821, 1 µM) and CHK1 (SRA-737, 1 µM).
A significant increase in L1 retrotransposition efficiency upon inhibition of ATR and CHK1
was observed in Huh7 cells (Figure 4A,B; effectiveness of the inhibitors against their
respective targets is shown in Figure S6A,B). However, there was no influence on the
L1orf1p level in Huh7 cells upon treatment with CHK1i (Figure S6C). ATR and CHK1 are
known to play an important role in the maintenance of DNA integrity in the face of DNA
damaging insults, principally through their involvement in the HRR response as well as
cell cycle checkpoints [41]. This supports the hypothesis that the HRR pathway is the main
DDR pathway involved in the regulation of L1-mediated genomic instability.
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3.4. Influence on L1 Retrotransposition and Its Consequences Persists after Viral Clearance
A number of ge es are reported to be dysregulated by HCV via pigen tic mechanisms
continuing beyond viral cl arance [18,19]. L kewi e, the consequences of L1-mediated
somatic mutag nesis will continue in cells beyond viral cl arance and may give r e to
new lineages of activ L1 copies. To address whether active viral infection is essential to
the upregulated retr transposition rate we observed in vitro, we treated H h7-J17 cells
with PSI7977 (sofosbuvir, a NS5B polymerase inhibitor that inhibits virus r plication).
As shown in Figure 2A, PSI7977 treatment produced a dose-dependent decrease in HCV
replicon levels in Huh7-J17 cells, as j dged by the overall luciferase activity of the cells.
The 10 µM dose was sele ted and Huh7-J17 cells were treated with 10 µM of PSI7977 in th
absence of puromycin for 3 weeks, to mimic DAA treatment in order t generate a cell line
that is clear of the virus, to be used as a post-HCV cleara ce o el (Huh7-J17+PSI7977).
The loss of the HCV replicon from the cells was confirmed by checking the puromycin
sensitivity of the cells post PSI7977 treatment. As expected, 100% cell death was observed
in Huh7-J17+PSI7977 cells upon puromycin treatment (2 µg/mL for 48 h). In addition,
no NS5A protein was detected in the Huh7-J17+PSI7977 whole cell lysate, confirming
the clearance of the HCV replicon from the cells (Figure 5A). Moreover, the L1orf1p level
dropped back to the parental Huh7 level upon viral clearance in Huh7-J17+PSI7977 cells
(Figures 5A and S7), indicating that the presence of the HCV transcript or its encoded
protein(s) is essential to upregulate L1orf1p.
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(HCV) replicon and the L1orf1p level 3 eeks after treat ent ith 10 I . Tubulin as
used as a loading control (A). Graph represents the fold change (FC) in the number of colonies
representing active retrotransposition (RTN) in Huh7-J17+PSI7977 cells compared to Huh7 cells
(B). Plates showing retrotransposition rates in indicated cell lines as assessed via blasticidin-based
selection of resistant colonies. Image is representative of 3 independent repeats. Numbers represent
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Next, EGFP- and blasticidin-based retrotransposition assays were carried out in Huh7-
J17+PSI7977 cells and compared with Huh7 and Huh7-J17 cells. Although lower than
Huh7-J17, the level of active retrotransposition remained upregulated in Huh7-J17+PSI7977
cells compared to Huh7 cells (fold change 2.48 ± 0.19, n = 3, p < 0.05 one-sample t-test
Figures 5B,C and S8), thus indicating that the influence of HCV on L1 retrotransposition
involves a ‘hit-and-run’ mechanism via pathway(s) which remain dysregulated in cells
even after viral clearance. The increased retrotransposition rate in Huh7-J17+PSI7977 cells
compared to Huh7 cells is further supported by the fact that the actual ability of the cells
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to attach and survive under blasticidin selection conditions when transfected with the
pcDNA6.1-blast control plasmid and seeded at a limited density was about 2-fold lower
compared to Huh7 cells (Figure S5).
The radiation sensitivity of Huh7-J17+PSI7977 cells was restored to the parental Huh7
cell level (Figures 5D and S9), with the plating efficiency also comparable to parental Huh7
cells (49% ± 5% for Huh7-J17+PSI7977 cells), indicating that the stress induced by HCV
replication and the dysregulation of DNA damage repair pathways returned to a steady
state level upon viral clearance. Plasmid-based DNA damage response assays confirmed
the restoration of the HRR pathway in Huh7-J17+PSI7977 cells (Figure 5E). Similar to Huh7-
J17 cells, there was no significant difference in NHEJ pathway between Huh7-J17+PSI7977
and Huh7 parental cells (Figure 5F). Hence, the underlying mechanisms regulating active
retrotransposition were different in the presence of active HCV infection versus post-viral
clearance, warranting further investigation.
4. Discussion
Our study provides evidence of L1 activation in the chronically infected HCV liver
and demonstrates that HCV infection can influence the L1 retrotransposition process. In
addition, we have demonstrated that the rate of retrotransposition remains enhanced even
after viral clearance, when compared to cells with no viral exposure. We have also demon-
strated that the presence of HCV exerted stress on the cells, rendering them more sensitive
to DNA damage. This is in line with a previous report, in which HCV-encoded NS5a is
shown to bind to RAD51AP1, leading to the impairment of the RAD51/RAD51AP1/UAF1
trimeric complex, thus impairing DNA repair and resulting in increased hypersensitivity to
DNA damaging agents [14]. On the other hand, HR factors are known to restrict retrotrans-
position, potentially by sterically blocking the formation of the second DNA nick during
L1 retrotransposition, perhaps by recruiting ssDNA-coating proteins RPA1 and Rad51 [40].
In summary, we observed increased retrotransposition in the HCV-infected cells, with
impaired DDR pathways as the potential mechanisms. However, how the influence of
HCV infection on L1 retrotransposition continues even after viral clearance is not known.
Of note, Schobel et al. recently reported a negative (rather than positive) influence of
HCV on the retrotransposition process [42], observing a reduction in L1 retrotransposition
in both Huh7.5 cells, which contains a mutation (Thr-55-Iso) in the RIG-I (DDX58) gene and
in Huh7 cells in the presence of HCV infection, which was attributed to an accumulation
of L1orf1p in the stress granules in the presence of the virus in their experiments. More
in keeping with our own studies, they observed an increase in retrotransposition on
overexpression of the HCV core protein, with upregulation of L1orf1p levels in the cells
in the presence of HCV. Discrepancies in the rates of retrotransposition are likely due to
differences in the model systems utilised, with both studies implicating L1s as a source
of genomic instability and recognising that cells have evolved multiple mechanisms to
suppress these elements and block retrotransposition [37]. HCV differentially modulates
several L1 inhibitory pathways, including the activation of autophagy and interferon
response pathways, whereas it impairs DNA damage repair pathways, especially HRR.
Hence, there is a delicate balance between these various pathways, which determines
the success or failure of active retrotransposition in a cell. The viral load can be a major
determinant of the extent of dysregulation of these processes and the final outcome of the
altered rate of active retrotransposition. In addition to HCV, the influence of other viruses
on L1—such as Kaposi’s sarcoma (KS)-associated herpesvirus—leading to the upregulation
of retrotransposition has been demonstrated (KSHV) [43], with contradictory reports about
the influence of human immunodeficiency virus (HIV) [44–46].
The present work extends the previous observation by Shukla et al. [21] that demon-
strated L1 activation and active retrotransposition in HCV-associated HCC by indicating
the possibility of L1 activation and HCV-supported active retrotransposition in the pre-
neoplastic liver. This suggests another potential contributing factor to be the underlying
cause of hepatocarcinogenesis in CHC patients as L1-mediated potential driver mutations
Cancers 2021, 13, 5079 13 of 17
have been implicated in various cancer types [22]. Before the DAA era, CHC patients were
treated with IFN therapy and type 1 interferons restrict L1 retrotransposition [47]. However,
the influence of DAAs on L1 activity is not known and is worth investigating further. In
addition, the comparison of the frequency of L1-mediated genomic rearrangements in HCV-
HCC developed in IFN therapy patients versus DAA therapy patients can shed light further
on the role of L1 in HCC development in CHC patients. In addition, L1 retrotransposition
can be inhibited by means of anti-retroviral drugs [48,49]. Many of these are currently in
clinical use, such as nucleoside reverse transcriptase inhibitors (NRTIs), e.g., lamivudine for
HBV and HIV therapy and non-nucleoside reverse transcriptase inhibitors (NNRTIs), e.g.,
efavirenz for HIV treatment [50]. Hence, it will be worth interrogating the effect of these
drugs on the rate of HCC development in patients co-infected with HBV-HCV (1–15% of
world population [51]) and HIV-HCV (~6.2% HIV-infected individuals [52]) and evaluate if
the HCC that developed in these patients is any different from only HCV-associated HCC,
especially in terms of L1-mediated genomic rearrangements.
Globally an estimated 130–170 million people (2–3% of the world’s population) are
living with HCV infection and more than 350,000 die of HCV-related conditions (includ-
ing HCC) per year [53]. Even if the sustained viral response (SVR) is attained via DAA
therapy, the risk of cancer persists in patients with advanced fibrosis or cirrhosis and these
individuals require ongoing surveillance for HCC [5,54,55]. Under the current guidelines,
monitoring for HCC with liver imaging and blood AFP (alpha-fetoprotein) biomarker
levels should be performed twice a year indefinitely post-SVR in patients with HCV cirrho-
sis [56]. Hence, understanding the risk of progression in an individual patient would have
enormous value to help develop stratified approaches to surveillance, better screening tools
and prevention. Progress in this field has been relatively slow, although genetic studies
show promise in the polymorphisms of some genes, such as programmed death recep-
tor 1 (PDCD1) [57], patatin-like phospholipase domain-containing 3 (PNPLA3) [58] and
transmembrane-6 superfamily member-2 (TM6SF2) [59], in combination with other risks
(sex, age, BMI, alcohol, type 2 diabetes), may ultimately play a role in stratified surveillance
for chronic liver disease patients [60]. For CHC patients, L1 activation should be explored
further as an HCC risk factor. Furthermore, as L1 activation can be monitored by mea-
suring the methylation status of L1 promoters in circulating cell-free DNA isolated from
peripheral blood [61,62], simple tests may be sufficient, without the need for the analysis
of tissue biopsies. Overall, the present study identifies L1 as a novel potential biomarker
for HCC risk prediction and a potential novel target to impede hepatocarcinogenesis in
CHC patients.
5. Conclusions
We have demonstrated that L1 expression in liver tissue can be upregulated in chronic
liver disease patients, years before HCC development, and this is especially observed in
CHC patients. L1 activation could be due to epigenetic changes as a field effect in the
liver due to chronic inflammation and increased oxidative stress, associated with chronic
liver disease. We have also demonstrated that HCV impairs the HRR pathways and
activates L1 retrotransposition. HCV also upregulated L1orf1p expression. Treatment of
Huh7 cells, an HCC cell line, with Chk1 inhibitor increased the L1 retrotransposition rate
but did not influence the L1orf1p level; hence, we speculate its mechanism to occur via
DDR-independent pathways. The exact causative relationship between these factors is not
known and warrants further investigation.
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of Western blot analysis of whole cell lysates of Huh7 (J7) and Huh7-J17 (J17/HCV) cells with
indicated antibodies, Figure S3: EGFP-based retrotransposition assay gating strategy, Figure S4:
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